TCTMD’s Top 10 Most Popular Stories for December 2019
EXCEL controversy dominated the month, but supplemental O2, structural imaging, and heparin concerns also made waves.
Related Articles
FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades
With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert predicts.
AI-Measured Breast Artery Calcification Tied to CV Outcomes in Women
The incidental mammogram finding isn’t a reason to panic, but it might a reason to make sure other risk factors are under control.
Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM
Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.
Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits
Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.
Heart Valve Matters Episode 3: RESHAPE-HF2
Michael Mack speaks with Stefan Anker about the outcomes and implications of the RESHAPE-HF2 trial.
‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF
Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.
‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM
While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on survival.
FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades
With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert predicts.
The ILUMIEN IV Trial
Ziad Ali and C. Michael Gibson take a deeper dive into this comparison of OCT- and angiography-guided PCI.
TCTMD’s Top 10 Most Popular Stories for September 2024
Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.